When people are most at risk of another stroke after a minor stroke or TIA
Kinetic analysis of acute stroke secondary prevention trials: Insights from combined datasets guiding future trial design
Researchers are combining past trial data to find the timing of highest risk for a second stroke after a minor stroke or TIA so treatments can be better timed.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11416242 on NIH RePORTER |
What this research studies
This project combines data from several past clinical trials to map how the risk of another ischemic stroke changes over time after a minor stroke or TIA. The team uses a mathematical 'kinetic' model that treats people as moving from a short-lived vulnerable state into a more stable state and estimates rates for those transitions and event risks. By fitting the model to trial results (including POINT, SOCRATES, and THALES), they aim to link different risk phases to likely biological mechanisms and to how treatments change those risks. The findings will be used to recommend timing and design features for future prevention trials and therapies.
Who could benefit from this research
Good fit: People who recently had a minor ischemic stroke or a transient ischemic attack (TIA), especially within days to a few weeks of the event, would be the most relevant group for future trials informed by this work.
Not a fit: People with hemorrhagic stroke, non-stroke neurological problems, or those whose stroke occurred many years ago are unlikely to directly benefit from this specific modeling project.
Why it matters
Potential benefit: If successful, this work could help doctors and researchers choose the best timing and duration for medications to prevent early recurrent strokes.
How similar studies have performed: Large trials like POINT, SOCRATES, and THALES showed high early recurrence risk and short-term treatment effects, and this project builds on those real-world trial results with a formal kinetic model.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Brorson, James R. — University of Chicago
- Study coordinator: Brorson, James R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.